Sareum Holdings PLC
15 November 2007
For immediate release 15 November 2007
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
AGM Statement
At the Company's annual general meeting held today, the following resolutions
were passed unanimously by shareholders on a show of hands.
The proxy votes received prior to the meeting on each resolution were as
follows:
ORDINARY RESOLUTIONS Votes Discretion Votes Votes
For Against Withheld
1.To receive and adopt the
Directors' report
and financial statements for the year 8,724,070 221,058 0 0
ended 30 June 2007. 97.53% 2.47% 0% 0%
2. To receive and adopt the
Remuneration
Committee report for the year ended 8,679,070 266,058 0 0
30 June 2007. 7.03% 2.97% 0% 0%
3.To re-elect Dr Paul Harper 8,724,070 221,058 0 0
as Director. 97.53% 2.47% 0% 0%
4.To re-elect Mr Giorgio
Reggiani as 8,576,070 366,058 3,000 0
Director. 95.88% 4.09% 0.03% 0%
5.To re-appoint Shipleys LLP
as auditors and
authorise the Directors to fix their 8,721,070 221,058 3,000 0
remuneration. 97.50% 2.47% 0.03% 0%
6.To authorise Directors for the
purposes of
section 80 of the Companies Act 1985
(the
Act) to allot relevant securities
(within 8,531,070 366,058 48,000 0
the meaning of that section) up to an 95.37% 4.09% 0.54% 0%
aggregate nominal amount of £90,000.
SPECIAL RESOLUTIONS Votes Discretion Votes Votes
For Against Withheld
7.Subject to the passing of resolution
6, to
authorise Directors, in accordance
with
section 95 of the Act, to allot
equity
securities (as defined in section 94
of
the Act) wholly for cash up to an 8,531,070 321,058 93,000 0
aggregate nominal amount of £50,000. 95.37% 3.59% 1.04% 0%
8.To authorise the Company to send or
supply
documents or information to
shareholders
by making them available on the 8,549,070 266,058 130,000 0
Company's 95.58% 2.97% 1.45% 0%
website or other electronic means.
For further information please contact:
Sareum Holdings +44 (0) 1223 497700
Tim Mitchell, Chief Executive Officer
Buchanan Communications +44 (0) 20 7466 5000
Tim Anderson, Mary-Jane Johnson
Notes for editors:
About Sareum Holdings plc
Sareum Holdings plc is a structure-based drug discovery business headquartered
in Cambridge, UK. Sareum Limited was formed in August 2003 to discover new drugs
for the treatment of cancer and to provide a range of drug discovery services to
the pharmaceutical industry. Sareum's unique approach aims to halve the time it
takes to discover new drug candidates.
A structure-based approach to drug discovery relies on knowledge of the
three-dimensional structure of the proteins that cause disease. Once the
structure is known, potential drugs are designed to 'lock-in' to the protein
with the aim of reversing or arresting a disease's progression. Knowledge of the
structure of the potential drugs and how they 'lock-in' to the protein permits
the best potential drug to be discovered. Determining structure is a complex
task and requires leading-edge equipment and experienced staff. Sareum's
approach to structure determination is to produce multiple recombinant proteins
primarily through a baculovirus expression system and to determine their
structure using x-ray crystallography.
When the structure is determined, the Company's innovative Template Screening
platform is used to identify novel chemical starting material designed to
interact with the target protein. Sareum then uses its high-throughput medicinal
chemistry platform to rapidly optimise these molecules and develop the most
promising into potential drug candidates.
Sareum provides its specialist drug discovery capabilities to partners in the
pharmaceutical and biotechnology industries. The Company aims to successfully
deliver: Programmes for complete gene-to-candidate structure-based discovery;
projects to accelerate or improve the productivity of specific activities; and
drug candidates for licensing at the Phase I or Phase II clinical trials stage.
Sareum joined the AIM market of the London Stock Exchange in October 2004 and
trades under the symbol SAR. For further information, please visit
www.sareum.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.